These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10652181)

  • 1. Use of vegetable-derived tween 80 for virus inactivation by solvent/detergent treatment.
    Roberts P; Sims G
    Biologicals; 1999 Sep; 27(3):263-4. PubMed ID: 10652181
    [No Abstract]   [Full Text] [Related]  

  • 2. Sindbis virus as a tool for quality control of viral inactivation of heated and chemically treated plasma-derived products.
    Espíndola OM; Belluci MS; Oliveira BC; Liberto MI; Cabral MC
    J Virol Methods; 2006 Jun; 134(1-2):171-5. PubMed ID: 16507321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparable virus inactivation by bovine or vegetable derived Tween 80 during solvent/detergent treatment.
    Seitz H; Blümel J; Schmidt I; Willkommen H; Löwer J
    Biologicals; 2002 Sep; 30(3):197-205. PubMed ID: 12217344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sample storage conditions on virus inactivation by solvent/detergent.
    Roberts P
    Biologicals; 2002 Sep; 30(3):255-7. PubMed ID: 12217349
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of manufacturing process parameters on virus inactivation by solvent-detergent treatment in a high-purity factor IX concentrate.
    Roberts PL; Dunkerley C
    Vox Sang; 2003 Apr; 84(3):170-5. PubMed ID: 12670365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations.
    Horowitz B; Wiebe ME; Lippin A; Stryker MH
    Transfusion; 1985; 25(6):516-22. PubMed ID: 3934801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tri(n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives.
    Edwards CA; Piet MP; Chin S; Horowitz B
    Vox Sang; 1987; 52(1-2):53-9. PubMed ID: 3111089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Removal and inactivation of enveloped and non-enveloped viruses during the purification of a high-purity factor IX by metal chelate affinity chromatography.
    Roberts PL; Walker CP; Feldman PA
    Vox Sang; 1994; 67 Suppl 1():69-71. PubMed ID: 8091741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products.
    Roberts P
    Biologicals; 2000 Mar; 28(1):29-32. PubMed ID: 10799053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
    Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
    Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced payload of lipid nanocarriers using supersaturated solution prepared by solvent-mediated method.
    Nguyen HM; Hwang IC; Kweon DK; Park HJ
    J Microencapsul; 2013; 30(7):657-66. PubMed ID: 23425086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virus inactivation in a factor VIII/VWF concentrate treated using a solvent/detergent procedure based on polysorbate 20.
    Roberts PL; Lloyd D; Marshall PJ
    Biologicals; 2009 Jan; 37(1):26-31. PubMed ID: 18848782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
    Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
    J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ensuring the pathogen safety of intravenous immunoglobulin and other human plasma-derived therapeutic proteins.
    Miller JL; Petteway SR; Lee DC
    J Allergy Clin Immunol; 2001 Oct; 108(4 Suppl):S91-4. PubMed ID: 11586272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adsorption behavior of lysozyme and Tween 80 at hydrophilic and hydrophobic silica-water interfaces.
    Joshi O; McGuire J
    Appl Biochem Biotechnol; 2009 Feb; 152(2):235-48. PubMed ID: 18478369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigations into the application of tri(n-butyl)phosphate/detergent mixtures to blood derivatives.
    Horowitz B
    Curr Stud Hematol Blood Transfus; 1989; (56):83-96. PubMed ID: 2642786
    [No Abstract]   [Full Text] [Related]  

  • 17. Microbial sterility testing of oil-formulated bovine somatotropin using Tween 80 dispersion.
    Workman WE; Clayton RA
    J Pharm Biomed Anal; 1996 Nov; 15(2):193-200. PubMed ID: 8933421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus validation studies of immunoglobulin preparations.
    Biesert L
    Clin Exp Rheumatol; 1996; 14 Suppl 15():S47-52. PubMed ID: 8828948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20.
    Weiszhár Z; Czúcz J; Révész C; Rosivall L; Szebeni J; Rozsnyay Z
    Eur J Pharm Sci; 2012 Mar; 45(4):492-8. PubMed ID: 21963457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effects of the microsphere suspending agent, Tween 80, in pigs.
    Grund F; Sommerschild HT; Kirkebøen KA; Ilebekk A
    Acta Physiol Scand; 1995 Nov; 155(3):331-2. PubMed ID: 8619333
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.